Study to Assess the Safety & Tolerability of a PARP Inhibitor in Combination With Gemcitabine in Pancreatic Cancer

Completed · Phase 1

Conditions studied: Pancreatic Neoplasms

In brief

The purpose of this study is to identify a safe and tolerable dose of the drug KU-0059436 that can be given in combination with gemcitabine chemotherapy for the treatment of pancreatic cancer.

Key facts

Study ID

NCT00515866

Run by

AstraZeneca

People needed

68

Starts

2007-08-01

Expected to finish

2012-07-01

Last updated by the study team

2013-12-20

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Histologically or cytologically confirmed adenocarcinoma of pancreas
• Locally advanced or metastatic unresectable disease

You may not qualify if…

• No prior anti cancer chemotherapy, radiotherapy (except palliative >4 weeks prior to entry, endocrine or immunotherapy or use of other investigational agents;

Where it is running

• Research Site — New York, New York, United States
• Research Site — Nashville, Tennessee, United States
• Research Site — London, United Kingdom
• Research Site — Oxford, United Kingdom

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.